Investor Presentaiton
Income Statement
Six Months Ended 30 June
RMB'million
Revenue
Cost of sales
2021
2020
1,941.8
984.2
(234.8)
(184.8)
Gross profit (IFRS Measure)
1,707.0
799.4
Other income
90.3
107.4
Research and development expenses
(1,042.1)
(808.0)
Administrative and other expenses
(340.9)
(186.8)
Selling and marketing expenses
(1,137.3)
(446.6)
Royalties and other related payments
(339.8)
(134.9)
Other gains and losses
(85.2)
97.5
Finance costs
(27.1)
(32.6)
Income tax expense
(0.2)
(3.5)
Loss for the period (IFRS Measure)
(1,175.3)
(608.2)
Adjustments to Non-IFRS measure
498.50
75.80
Loss for the period (Non-IFRS Measure)
(676.8)
(532.4)
Note: Numbers may not add due to rounding
Innovent
Confidential
Copyright©2021 Innovent Biologics
Revenue
In the first half year of 2021, we generated total revenue of
RMB1,941.8 million, including RMB1,854.6 million driven
by product sales coupled with RMB87.2 million from
License fee income.
Expenses
R&D investments were spending on clinical trials of late-
stage and prioritized assets from our robust pipeline
globally to further expand our existing product line's
indications as well as developing new products in our pipe
line, including pre clinical product developments.
The planned increase in S&M expenses was due to broader
commercialisation activities with respect to
TYVYTⓇ(sintilimab injection), BYVASDAⓇ (bevacizumab
biosimilar), SULINNOⓇ (adalimumab biosimilar) and
HALPRYZAⓇ(rituximab biosimilar)
IFRS loss for the period
IFRS loss for the period was RMB1,175.3 million
Non-IFRS loss for the period
Non-IFRS loss was RMB676.8 million. Adjustments to IFRS
measure include share-based compensation expenses and
net foreign exchange gains or losses.
42View entire presentation